Anti-VEGFA antibody [SP28], prediluted (ab27620)


  • Product nameAnti-VEGFA antibody [SP28], prediluted
    See all VEGFA primary antibodies
  • Description
    Rabbit monoclonal [SP28] to VEGFA, prediluted
  • Tested applicationsSuitable for: IHC-Pmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide corresponding to Human VEGFA (N terminal).

  • Positive control
    • Tumor cells in hemangiosarcomas


Our Abpromise guarantee covers the use of ab27620 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P 1/1. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.

Boil tissue section in 10mM citrate buffer, pH 6.0 for 10 min followed by cooling at room temperature for 20 min.


  • FunctionGrowth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.
  • Tissue specificityIsoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed.
  • Involvement in diseaseDefects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:603933]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.
  • Sequence similaritiesBelongs to the PDGF/VEGF growth factor family.
  • Cellular localizationSecreted. VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a signicant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin.
  • Information by UniProt
  • Database links
  • Alternative names
    • MGC70609 antibody
    • MVCD1 antibody
    • Vascular endothelial growth factor A antibody
    • vascular endothelial growth factor antibody
    • Vascular permeability factor antibody
    • VEGF A antibody
    • Vegf antibody
    • VEGF-A antibody
    • VEGF120 antibody
    • Vegfa antibody
    • VEGFA_HUMAN antibody
    • VPF antibody
    see all

Anti-VEGFA antibody [SP28], prediluted images

  • Immunohistochemical staining of human angiosarcoma labelling VEGF (SP28) with ab27620 at a 1:1 no dilution.

  • Paraffin embedded formalin fixed human angioscarcoma tissue section stained with prediluted anti VEGF antibody ab27620.

References for Anti-VEGFA antibody [SP28], prediluted (ab27620)

This product has been referenced in:
  • Schaefer IM  et al. Pyloric gland adenoma of the cystic duct with malignant transformation: report of a case with a review of the literature. BMC Cancer 12:570 (2012). Human . Read more (PubMed: 23206236) »
  • Biswas S  et al. Effects of HIF-1alpha and HIF2alpha on Growth and Metabolism of Clear-Cell Renal Cell Carcinoma 786-0 Xenografts. J Oncol 2010:757908 (2010). IHC-P ; Human . Read more (PubMed: 20652061) »

See all 4 Publications for this product

Product Wall

Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Blocking step H2O2 as blocking agent for 10 minute(s) · Concentration: 3% · Temperature: 25°C
Antigen retrieval step Heat mediated - Buffer/Enzyme Used: citrate, pH6.0, 20 min at 100C
Sample Human Tissue sections (Osteosarcoma, Breast Carcinoma)
Specification Osteosarcoma, Breast Carcinoma
Permeabilization No
Fixative Formaldehyde

Abcam user community

Verified customer

Submitted Feb 26 2015

Thank you for contacting us and your interest in our products.

We do not have any experimental data regarding the specificity of the anti-VEGF antibody (ab27620)to the various isoforms of VEGF-A.By sequence homology of the immunogen use...

Read More

Thank you for contacting Abcam regarding ab27620, lot# GR6603-1. Unfortunately, we do not have anymore of lot#GR6603-1 available. If there is anything else I can help you with, please let me know.

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample Human Tissue sections (hemangioma)
Specification hemangioma
Fixative Formaldehyde
Antigen retrieval step Heat mediated - Buffer/Enzyme Used: pH 6.0
Permeabilization No
Blocking step Serum as blocking agent for 10 minute(s) · Concentration: 10%

Abcam user community

Verified customer

Submitted Feb 26 2009